Viatris Inc is a global healthcare company that focuses on providing access to medicines, including generic and specialty pharmaceuticals, to improve patient health outcomes worldwide
Formed from the merger of Mylan and Upjohn, a division of Pfizer, Viatris leverages its extensive portfolio to develop and manufacture a wide range of high-quality medications that address diverse therapeutic areas. With a commitment to sustainability and innovation, the company emphasizes collaboration with healthcare providers, policymakers, and communities to enhance the accessibility and affordability of essential healthcare solutions for patients around the globe.
Viatris Inc. is a wholly owned subsidiary of Pfizer that specializes in off-patent drugs. Share price fell about 4% in the past year from $11.88 to $11.41, as of Thursday’s market close.
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.
There are endless ways of analyzing price data. But the truth is, I don’t use 90% of it. What I find most useful when analyzing stock charts is pattern recognition. Today, I’ll review three of the patterns that I use regularly in my trading research.
The S&P 500 enjoyed a strong year in 2021, the first year with Joe Biden in the White House. Not all stocks were up and past results could show sectors to avoid ahead of the 2024 election.
Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support.
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
CC Lagator of Options AI warns traders to expect increased volatility in the week after September's 'triple witching,' with over $5 trillion in options expiring and historical evidence of market turbulence. VIX at 16 presents attractive opportunities for call option buyers.
Viatris reports Q2 revenue of $3.78 billion, with strong growth in Greater China and new product launches driving results. Adjusted EPS of $0.69 beats estimates, and the company raises its 2024 sales outlook to $14.6 -$15.1 billion.
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.
Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your portfolio?
Viatris reports Q1 EPS in line with consensus at $0.67, with sales slightly missing expectations at $3.66 billion. Strong growth in Emerging Markets and Europe offset by challenges in North America. Guidance adjusted slightly downward for 2024.
Wall Street is seeing a day of gains as all major indices traded in the green around noon in New York, driven by a surprising uptick in unemployment claims prompting speculation over Federal Reserve interest rate cuts.
